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second reviewer was up to 3% more sensitive than the ﬁrst. In the
ovarian cancer, anti-infectives, hyperlipidemia, and clinical
breast cancer reviews, the second reviewer was up to 2% more
speciﬁc than the ﬁrst; all were signiﬁcant differences apart from
the clinical breast cancer review. In the cases where the second
reviewer was less sensitive or speciﬁc than the ﬁrst, these differ-
ences were non-signiﬁcant. CONCLUSIONS: While ﬁrst and
second reviewers tend to have similar sensitivity in including
citations, second reviewers tend to be more accurate at excluding
citations. This may be explained by the fact that, since more
caution is exercised in excluding citations than including them,
reviewers may wait until they have gained sufﬁcient experience to
make this decision.
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OBJECTIVES: To determine 12-months administrative preva-
lence rate of tic disorders (TD) and Tourette syndrome (TS), as
well as their coexistence with ADHD in a large German commu-
nity sample, against the background of the clinical importance of
this association. METHODS: Data for patients with a diagnosis
of any tic disorder (F95, ICD-10), Tourette disorder (F95.2), or
ADHD (F90.0 and/or F90.1) were extracted from the Nord-
baden claims database, covering the complete subpopulation
insured by Statutory Health Insurance (2.238 million lives in
2003; for comparison: total German population insured by SHI
in 2003, 70.2 million) in Nordbaden in South-Western Germany
(representing 82% of the total regional population). RESULTS:
A total of 3,618 patients with a diagnosis of any TD (hereof, 215
with TS) and 11,875 patients with ADHD were identiﬁed, cor-
responding to overall administrative prevalence rates (across all
age groups) of 0.16% (TD), 0.01% (TS), and 0.53% (ADHD).
Males were generally more often afﬂicted with any of the disor-
ders analyzed than females (TD, 0.19% versus 0.13% for
females; TS, 0.02% versus 0.01%; ADHD, 0.83% versus
0.27%). TD and TS were most prevalent among children 7–12
years (0.79% and 0.04%, respectively), and were signiﬁcantly
associated with presence of ADHD. ADHD was reported in
11.2% of children age 12 years with TD (boys, 15.4%; girls,
4.5%), compared to 3.1% (boys, 4.4%; girls, 1.7%) in the
community covered. Among adolescents (age 13–18 years), a
diagnosis of ADHD was tenfold more likely in patients with TD
(15.1%; boys, 18.5%; girls, 7.7%) compared with the commu-
nity group (1.5%; boys, 2.3%; girls, 0.7%). CONCLUSIONS:
These data extend the epidemiological database by providing for
the ﬁrst time information from Germany on the administrative
prevalence of TD, TS, and ADHD, as well as their coexistence,
hereby highlighting the relevance of taking comorbidity into
account when designing health care utilization and burden of
disease studies.
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OBJECTIVES: The majority (50–80%) of patients with general-
ized anxiety disorder (GAD) suffer from a variety of sleep prob-
lems. The objective of this study was to measure the direct effect
of anxiolytic treatment and, separately, its indirect effect medi-
ated by anxiety symptoms on sleep disturbance in patients with
GAD. METHODS: Data were obtained from an 8-week, double-
blind, randomized, ﬂexible-dose, placebo- and active-control
study in 372 GAD patients. Patients were assigned to pre-
gabalin (300–600 mg/day), venlafaxine XR (75–225 mg/day),
or placebo. Anxiety symptoms were measured by clinician-
administered HAM-A scale at baseline and on weeks 1–4, 6, and
8 and sleep disturbances were measured using the 4-item sleep
disturbance subscale on Medical Outcomes Study Sleep Scale
(MOS-SS), a validated patient-reported outcome measure. Statis-
tical mediation modeling was used to estimate the direct effects of
pregabalin and venlafaxine XR (relative to placebo) and the
indirect effects via anxiety symptoms, the mediator variable, as
measured by HAM-A total score. All available data from the trial
were used in the statistical analyses. RESULTS: Patients were
predominantly female (61%) and had a mean age of 41 years.
Path coefﬁcients for direct and indirect (mediated) paths for
patients in the pregabalin group indicated less sleep disturbance
with treatment. Fifty-three percent of the reduction in sleep dis-
turbance was due to the direct effect of pregabalin (p = 0.007).
The remainder of the reduction in sleep disturbance (47%, p =
0.015) was mediated via anxiety symptoms. In contrast, there
was no difference in sleep disturbance (p = 0.58) between patients
treated with venlafaxine XR or placebo. CONCLUSIONS: The
underlying relationships between treatment, anxiety symptoms,
and sleep disturbance are explicitly described and partitioned
through mediation modeling. About half of the total improve-
ment in sleep disturbance was identiﬁed as being due to the
direct effect of pregabalin independent of an effect on anxiety
symptoms.
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OBJECTIVES: To evaluate preliminary treatment outcomes of
Russian patients enrolled in the electronic-Schizophrenia Treat-
ment Adherence Registry (e-STAR) followed up for three months
after initiating treatment with risperidone long-acting injectable
(RLAI). METHODS: e-STAR is an international, prospective,
observational study of schizophrenia patients initiated on RLAI.
Psychiatric hospitalisations and medication use are collected ret-
rospectively for one year and prospectively every three months
for two years. Clinical and functioning outcomes, which are
measured by the Clinical Global Impression Severity (CGI-S)
Scale and the Global Assessment of Functioning (GAF) Scale,
respectively, are assessed prospectively every three months for
two years. McNemar’s test and paired-t test were used to evalu-
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ate changes in categorical and continuous variables, respectively.
RESULTS: Total of 102 patients who were followed up for 3
months are included in this analysis. Of which, 43.1% were
male, mean age was 38.5  12.6 years old, and mean time since
diagnosis was 8.9  8.4 years. The ﬁrst reasons for initiating
RLAI were insufﬁcient response to previous medication (43.1%)
and need for maintenance (24.5%). At 3-months, 98% of
patients were still on RLAI treatment. Comparing the ﬁrst
3-month treatment of RLAI to the 3-month period prior to the
initiation of RLAI for the 102 patients, signiﬁcant decreases were
observed in the proportion of patients hospitalized (26.5% vs.
2.9%, p < 0.001) and the mean number of days in hospital (10.2
days vs. 1.3 days, p < 0.001). By 3-months, there were signiﬁcant
improvements in disease severity and patient functioning; the
average CGI-S score signiﬁcantly decreased from 3.74 at baseline
to 3.33 at 3 months (p < 0.001) and the mean GAF score
signiﬁcantly increased from 51.5 at baseline to 56.0 at 3 months
(p < 0.001). CONCLUSIONS: Based on the 3-month interim
results, treatment with RLAI was associated with reductions in
hospitalizations and improvements in disease severity and patient
functioning in Russian patients with schizophrenia.
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OBJECTIVES: Atypical antipsychotics are widely used in the
pharmacologic management of schizophrenia. A meta-analysis of
oral atypical antipsychotics was conducted to assess the relative
effectiveness of a newly introduced agent, paliperidone extended-
release (ER). METHODS: Randomized placebo-controlled
studies of risperidone, olanzapine, quetiapine and aripiprazole
were identiﬁed via a database search (MEDLINE, Embase, the
Cochrane Library, PsycInfo and the Cumulative Index to Nursing
& Allied Health Literature). Baseline demographic, efﬁcacy and
safety data were extracted and combined in the meta-analysis
using the DerSimonian and Laird approach [1]. Random effects
meta-regression1 was used to assess potential confounding by
patient mean age, gender ratio and duration of therapy on vari-
ability in efﬁcacy and safety. RESULTS: Atypical antipsychotics
as a group had lower odds of withdrawal for any reason than
placebo treatment (OR 0.52, 95%CI 0.46, 0.58), with paliperi-
done ER having lower odds than the antipsychotic class as a
whole (OR 0.43, 95%CI 0.34, 0.53). Odds of withdrawal due to
adverse events were lower with paliperidone ER (OR 0.88,
95%CI 0.71, 1.15) than with risperidone (OR 2.09, 95%CI
0.80, 5.41) and with the atypical antipsychotics as a class (OR
1.02, 95%CI 0.83, 1.25). Paliperidone ER was associated with a
lower odds of somnolence (OR 1.33, 95%CI 0.92, 1.94) than the
atypical class (OR 1.70, 95%CI 1.39, 2.09) and a lower odds of
weight gain (OR 1.75, 95%CI 1.29, 2.37) than all of the atypical
antipsychotics, including risperidone (OR 3.08, 95%CI 1.53,
6.20). The predominant factor in the observed variability in
efﬁcacy was the speciﬁc antipsychotic, rather than patient-related
factors or duration of therapy. CONCLUSIONS: Within the
spectrum of efﬁcacy and safety of the class, Paliperidone ER
demonstrates a unique efﬁcacy and tolerability proﬁle. Owing to
the heterogeneity within the class, information on individual
beneﬁt/risk proﬁles of atypical antipsychotics is necessary for
selecting a speciﬁc treatment for each patient. [1] DerSimonian
R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
1986;7:177–88.
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OBJECTIVES: Serotonin is critical for maintaining platelet hae-
mostatic function such as aggregation. SSRI-induced upper
gastrointestinal hemorrhage (UGIH) may occur through SSRI-
induced inhibition of serotonin reuptake by platelets, leading to
depletion of serotonin after several weeks of antidepressant (i.e.
SSRI) treatment. The risk of SSRI-induced-UGIH has not been
documented in a U.S. managed care population. The purpose of
this study was to compare the incremental likelihood of UGIH
events with use of SSRIs and in combination with NSAIDs in a
managed care population. METHODS: A retrospective study
was designed using data from a large managed care claims data-
base. Subjects were identiﬁed anytime between October 1, 2005
to September 30, 2006 (index-period) and classiﬁed into SSRI-
users, NSAID-users or SSRI-NSAID concomitant users. Each
subject was matched to a control (non-SSRI/NSAID-user) based
on their index date. All subjects were treatment naïve 12 months
prior to their pre-index period and followed for 12 months post
index date to determine the risk of any UGIH event based on
ICD-9-CM code. RESULTS: A total of 87,054, 275,476, 27,696,
and 386,248 subjects were identiﬁed as SSRI-users, NSAID-
users, concomitant-users and controls at index-period. The
control group was signiﬁcantly (p < 0.001) younger than the drug
cohorts (31vs. 42years), lower (p < 0.001) proportions of females
(47% vs. 57%), and lower (p < 0.001) burden of comorbid
illness as measured by Charlson Comorbidity Index (0.15 vs.
0.50). Compared to the controls, concomitant-users had 1.0%
(OR = 3.32; 95%CI = 2.90–3.79), SSRI-users had 0.8% (RR =
2.59; 95%CI = 2.36–2.86), and NSAID-users had 0.5% (RR =
1.83; 95%CI = 1.69–1.97) cases with a diagnoses of UGIH.
CONCLUSIONS: Current SSRIs that are recommended as ﬁrst
line therapy for depression is associated with a risk of UGIH
within ﬁrst 12-months either alone or in combination with
NSAIDs. Future research needs to estimate the economic burden
of such bleeding events to managed care.
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OBJECTIVES: To determine the epidemiological, clinical, and
economic burden of bipolar disorder (BD) in Europe.
METHODS: A systematic review of publications from the last 10
years relating to the burden of bipolar disorder was conducted,
including studies on epidemiology, patient-related issues, and
costs. RESULTS: Data from the UK, Germany, and Italy indi-
cated a prevalence of bipolar disorder of ~1%, and a misdiag-
nosis rate of 70% from Spain. In one study, up to 75% of
patients had at least one DSM-IV comorbidity, commonly
anxiety disorders and substance/alcohol abuse. Attempted
suicide rates varied between 21–54%, with 18% mortality in the
UK. The chronicity of bipolar disorder exerted a profound and
debilitating effect on the patient. Only 30% of German patients
were employed full time at a level matching their qualiﬁcations.
In Italy, 63–67% of patients were unemployed and in Germany,
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